Sec Form 3 Filing - Lehrer-Graiwer Joshua @ Global Blood Therapeutics, Inc. - 2019-10-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lehrer-Graiwer Joshua 2. Issuer Name and Ticker or Trading Symbol Global Blood Therapeutics, Inc. [ GBT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BLVD., SUITE 300 3. Date of Earliest Transaction (MM/DD/YY) 10/01/2019 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 3.4 ( 1 ) 03/04/2025 Common Stock 625 D Stock Option (Right to Buy) $ 20 ( 2 ) 08/10/2025 Common Stock 894 D Stock Option (Right to Buy) $ 12.95 ( 3 ) 02/08/2026 Common Stock 3,125 D Stock Option (Right to Buy) $ 19.89 ( 4 ) 09/07/2026 Common Stock 6,563 D Stock Option (Right to Buy) $ 26.9 ( 5 ) 02/16/2027 Common Stock 17,063 D Restricted Stock Units $ 0 ( 6 )( 7 ) ( 7 ) Common Stock 5,250 D Stock Option (Right to Buy) $ 27.9 ( 8 ) 07/25/2027 Common Stock 12,500 D Restricted Stock Units $ 0 ( 6 )( 9 ) ( 9 ) Common Stock 4,150 D Restricted Stock Units $ 0 ( 6 )( 10 ) ( 10 ) Common Stock 4,000 D Stock Option (Right to Buy) $ 59.6 ( 11 ) 01/31/2028 Common Stock 26,500 D Restricted Stock Units $ 0 ( 6 )( 12 ) ( 12 ) Common Stock 10,625 D Restricted Stock Units $ 0 ( 6 )( 13 ) ( 13 ) Common Stock 20,563 D Stock Option (Right to Buy) $ 48.44 ( 14 ) 01/31/2029 Common Stock 35,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lehrer-Graiwer Joshua C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO, CA94080 Chief Medical Officer Signatur es /s/Lesley Ann Calhoun, as Attorney-in-Fact 10/03/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents stock options outstanding from an original grant of options to purchase 10,000 shares of Common Stock. The shares of Common Stock underlying the original option grant are fully vested. ( 2 )Represents stock options outstanding from an original grant of options to purchase 14,300 shares of Common Stock. The shares of Common Stock underlying the original option grant are fully vested. ( 3 )Represents stock options outstanding from an original grant of options to purchase 10,000 shares of Common Stock. The shares of Common Stock underlying the original option grant shall vest in 16 equal quarterly installments over 4 years from February 9, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 4 )Represents stock options outstanding from an original grant of options to purchase 15,000 shares of Common Stock. The shares of Common Stock underlying the original option grant shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 5 )Represents stock options outstanding from an original grant of options to purchase 21,000 shares of Common Stock. The shares of Common Stock underlying the original option grant shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 6 )Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. ( 7 )The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from March 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 8 )The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from July 26, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 9 )The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from August 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 10 )The shares of Common Stock underlying the RSUs shall vest upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 11 )The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 12 )The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 13 )The shares of Common Stock underlying the RSUs shall vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. ( 14 )The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks: Exhibit 24.1 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.